Ovarian, fallopian tube or primary peritoneal cancers - Keytruda, Avastin and Cyclophosphamide
Ovarian Cancer – 95% benefit with Keytruda, Avastin and Cyclophosphamide
Background Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable and effective therapies. About the…